News archive 2010

Clinical trial findings challenge clinical practice

25 Aug 2010, PR 179/10

Patients with coronary artery disease undergoing angioplasty do not benefit from having their circulation artificially supported with a balloon pump as a preventative measure during angioplasty, according to the first randomised trial studying the practice and published today in the Journal of the American Medical Association (JAMA).

The trial was carried out across 17 tertiary referral cardiac centres in the UK and was designed and led by Dr Divaka Perera and Dr Simon Redwood, interventional cardiologists at Guy's and St Thomas' Foundation Trust in London1. The study was funded by unrestricted educational grants and the principal investigators were supported by the atherosclerosis theme of the National Institute for Health Research (NIHR) comprehensive Biomedical Research Centre at Guy's and St Thomas' and King's College London.

Angioplasty is a common procedure performed under local anaesthetic to open up the narrowed sections of a patient's arteries. A small balloon is inflated within the narrowed artery to open the blockage, and a metal scaffold (stent) is inserted to keep the artery open. Patients with poor heart function and extensively narrowed heart arteries are at higher risk of complications following angioplasty and there has been much interest in the balloon pump as a means of reducing such adverse events.

When a balloon pump is used, it is placed inside the patient's aorta (the main artery supplying blood to the body) to provide circulatory support to their failing hearts. Over the last 20 years, cardiologists across the world have adopted use of the balloon pump as a preventative measure during high risk angioplasty, but this common practice has been based on anecdotal accounts and small observational studies, which are limited by selection bias.

The Balloon pump assisted Coronary Intervention Study (BCIS-1) involved 301 patients with severe left ventricular dysfunction and extensive coronary artery disease. They were randomly assigned to either have the balloon pump inserted before angioplasty or to have angioplasty without planned balloon pump support.

There was no difference in the proportion of patients who suffered major cardiovascular complications (comprising death, acute myocardial infarction, cerebrovascular events or further revascularisation, at hospital discharge capped at 28 days) in the group who received a balloon pump beforehand (15.2%), compared to those who did not (16%). However, approximately one in eight of the latter group required an emergency balloon pump insertion during the procedure, emphasising the importance of having a balloon pump on standby when undertaking such cases2.

Confirmation of safety benefits expected

Dr Simon Redwood, Reader in Interventional Cardiology at King's College London and Honorary Consultant Cardiologist at Guy's and St Thomas' said: 'For many years we have strongly advocated the use of the balloon pump to support patients' circulatory system during high risk coronary angioplasty and wanted to build up definitive evidence to support its use. We believed this multi-centre study would establish once and for all the clinical and safety benefits of using the pump as a preventative measure.

'However, rather than demonstrating the benefits, we found that inserting a balloon pump into the aorta as a preventative measure has little or no impact on the incidence of major complications and death in high risk cardiac patients, although there is still an important role for using a pump in an emergency.

'Angioplasty is now the most common interventional treatment for treating coronary artery disease. The study findings raise important questions about current clinical practice and whether it is necessary to use a balloon pump routinely during the procedure. The findings may reflect the fact that angioplasty has become a less risky procedure over time as cardiologists have increased their skills.'

Dr Martyn Thomas, lead of the cardiovascular clinical academic group at King's Health Partners Academic Health Science Centre, said: 'It is vitally important that high quality research underpins clinical practice, and studies such as this are key to informing cardiac practice nationally and internationally.'

The cardiac units at Guy's and St Thomas' and King's College Hospital NHS Foundation Trusts, the two acute Trusts within King's Health Partners, jointly perform approximately 3000 interventional cardiology procedures a year, and form one of the biggest cardiac centres in the UK.

Notes to editors

1. Perera D, Stables R, Booth J, Thomas M, Redwood S. The balloon pump-assisted coronary intervention study (BCIS-1): rationale and design. Am Heart J. 2009; 158(6): 910-916

2. Perera D, Stables R, Thomas M, Booth J, Pitt M, Blackman D, De Belder A, Redwood S. Elective Intra-aortic balloon counterpulsation during high-risk percutaneous coronary intervention: a randomized controlled trial. JAMA 2010; 304(8) in press

17 hospitals recruited patients into this study. Over half of the patients were recruited into the study at: St Thomas' Hospital, Birmingham Heartlands Hospital, Brighton and Sussex University Hospital, Leeds Teaching Hospitals and Liverpool Heart and Chest Hospital


King's College London
King's College London is one of the top 25 universities in the world (Times Higher Education 2009) and the fourth oldest in England. A research-led university based in the heart of London, King's has nearly 23,000 students (of whom more than 8,600 are graduate students) from nearly 140 countries, and some 5,500 employees. King's is in the second phase of a £1 billion redevelopment programme which is transforming its estate.

King's has an outstanding reputation for providing world-class teaching and cutting-edge research. In the 2008 Research Assessment Exercise for British universities, 23 departments were ranked in the top quartile of British universities; over half of our academic staff work in departments that are in the top 10 per cent in the UK in their field and can thus be classed as world leading. The College is in the top seven UK universities for research earnings and has an overall annual income of nearly £450 million.

King's has a particularly distinguished reputation in the humanities, law, the sciences (including a wide range of health areas such as psychiatry, medicine, nursing and dentistry) and social sciences including international affairs. It has played a major role in many of the advances that have shaped modern life, such as the discovery of the structure of DNA and research that led to the development of radio, television, mobile phones and radar. It is the largest centre for the education of healthcare professionals in Europe; no university has more Medical Research Council Centres.

King's College London and Guy's and St Thomas', King's College Hospital and South London and Maudsley NHS Foundation Trusts are part of King's Health Partners. King's Health Partners Academic Health Sciences Centre (AHSC) is a pioneering global collaboration between one of the world's leading research-led universities and three of London's most successful NHS Foundation Trusts, including leading teaching hospitals and comprehensive mental health services. For more information, visit: www.kingshealthpartners.org.



Further information
Andrea Ttofa
Guy's and St Thomas' NHS Foundation Trust
Tel: +44 (0)20 7188 5577
Email: andrea.ttofa@gstt.nhs.uk.


Next:
King’s business plan competition launched
Honorary Fellow wins Nobel Literature Prize
King's contributes to WHO Intervention Guidelines
Nightingale app previewed
Free radicals shown to protect the heart

Previous:
Chairman of Marjan Centre appointed
Second Wellcome Drug Discovery award success
Student satisfaction increases
Stories of the Strand
Materials scientist to give RI Lecture


This information is provided by the Public Relations Department
Tel: 020-7848 3202  Fax: 020-7848 3739  Email: pr@kcl.ac.uk